Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice.
bevacizumab
real‐world setting
recurrent glioblastoma
survival
treatment patterns
Journal
Health science reports
ISSN: 2398-8835
Titre abrégé: Health Sci Rep
Pays: United States
ID NLM: 101728855
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
31
07
2018
revised:
06
11
2018
accepted:
04
01
2019
entrez:
4
5
2019
pubmed:
3
5
2019
medline:
3
5
2019
Statut:
epublish
Résumé
This retrospective review of patients with recurrent glioblastoma treated at the Preston Robert Tisch Brain Tumor Center investigated treatment patterns, survival, and safety with bevacizumab in a real-world setting. Adult patients with glioblastoma who initiated bevacizumab at disease progression between January 1, 2009, and May 14, 2012, were included. A Kaplan-Meier estimator was used to describe overall survival (OS), progression-free survival (PFS), and time to greater than or equal to 20% reduction in Karnofsky Performance Status (KPS). The effect of baseline demographic and clinical factors on survival was examined using a Cox proportional hazards model. Adverse event (AE) data were collected. Seventy-four patients, with a median age of 59 years, were included in this cohort. Between bevacizumab initiation and first failure, defined as the first disease progression after bevacizumab initiation, biweekly bevacizumab and bevacizumab/irinotecan were the most frequently prescribed regimens. Median duration of bevacizumab treatment until failure was 6.4 months (range, 0.5-58.7). Median OS and PFS from bevacizumab initiation were 11.1 months (95% confidence interval [CI], 7.3-13.4) and 6.4 months (95% CI, 3.9-8.5), respectively. Median time to greater than or equal to 20% reduction in KPS was 29.3 months (95% CI, 13.8-∞). Lack of corticosteroid usage at the start of bevacizumab therapy was associated with both longer OS and PFS, with a median OS of 13.2 months (95% CI, 8.6-16.6) in patients who did not initially require corticosteroids versus 7.2 months (95% CI, 4.8-12.5) in those who did ( Treatment patterns and outcomes for patients with recurrent glioblastoma receiving bevacizumab in a real-world setting were comparable with those reported in prospective clinical trials.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
This retrospective review of patients with recurrent glioblastoma treated at the Preston Robert Tisch Brain Tumor Center investigated treatment patterns, survival, and safety with bevacizumab in a real-world setting.
METHODS
METHODS
Adult patients with glioblastoma who initiated bevacizumab at disease progression between January 1, 2009, and May 14, 2012, were included. A Kaplan-Meier estimator was used to describe overall survival (OS), progression-free survival (PFS), and time to greater than or equal to 20% reduction in Karnofsky Performance Status (KPS). The effect of baseline demographic and clinical factors on survival was examined using a Cox proportional hazards model. Adverse event (AE) data were collected.
RESULTS
RESULTS
Seventy-four patients, with a median age of 59 years, were included in this cohort. Between bevacizumab initiation and first failure, defined as the first disease progression after bevacizumab initiation, biweekly bevacizumab and bevacizumab/irinotecan were the most frequently prescribed regimens. Median duration of bevacizumab treatment until failure was 6.4 months (range, 0.5-58.7). Median OS and PFS from bevacizumab initiation were 11.1 months (95% confidence interval [CI], 7.3-13.4) and 6.4 months (95% CI, 3.9-8.5), respectively. Median time to greater than or equal to 20% reduction in KPS was 29.3 months (95% CI, 13.8-∞). Lack of corticosteroid usage at the start of bevacizumab therapy was associated with both longer OS and PFS, with a median OS of 13.2 months (95% CI, 8.6-16.6) in patients who did not initially require corticosteroids versus 7.2 months (95% CI, 4.8-12.5) in those who did (
CONCLUSIONS
CONCLUSIONS
Treatment patterns and outcomes for patients with recurrent glioblastoma receiving bevacizumab in a real-world setting were comparable with those reported in prospective clinical trials.
Identifiants
pubmed: 31049419
doi: 10.1002/hsr2.114
pii: HSR2114
pmc: PMC6482327
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e114Déclaration de conflit d'intérêts
Annick Desjardins has received grants or research support from Genentech, PTC Therapeutics, Celldex, Triphase Research and Development Corp, Eli Lilly and Co, Eisai, Symphogen A/S, Pfizer, and Orbus Therapeutic and is an advisory board member for Genentech; Arliene Ravelo is an employee of Genentech and owns stock options in Roche; Nicolas Sommer is an employee of Genentech and owns stock options in Roche; and the remaining authors have no conflicts of interest to declare.
Références
J Clin Oncol. 1999 Aug;17(8):2572-8
pubmed: 10561324
Lancet Oncol. 2014 Aug;15(9):943-53
pubmed: 25035291
J Natl Compr Canc Netw. 2011 Apr;9(4):403-7
pubmed: 21464145
South Asian J Cancer. 2015 Oct-Dec;4(4):163-73
pubmed: 26981507
Br J Cancer. 2000 Sep;83(5):588-93
pubmed: 10944597
Eur J Cancer. 2012 May;48(8):1176-84
pubmed: 22464345
J Clin Oncol. 2009 Oct 1;27(28):4733-40
pubmed: 19720927
J Neurooncol. 2015 May;122(3):595-605
pubmed: 25773061
Oncologist. 2009 Nov;14(11):1131-8
pubmed: 19897538
J Oncol Pharm Pract. 2018 Jan;24(1):33-36
pubmed: 27903792
Cancer Res. 2004 Oct 1;64(19):6892-9
pubmed: 15466178
Clin Cancer Res. 2003 Apr;9(4):1399-405
pubmed: 12684411
Health Sci Rep. 2019 Feb 13;2(4):e114
pubmed: 31049419
J Clin Oncol. 2009 Feb 10;27(5):740-5
pubmed: 19114704
Neuro Oncol. 2010 Feb;12(2):164-72
pubmed: 20150383
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Drugs Context. 2015 Mar 10;4:
pubmed: 25834620